Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

Increased momentum in the kidney disease space, sparked in part by an evolution in FDA's thinking about approvable endpoints, encouraged a VC syndicate to back newly launched Chinook with $65 million in series A funding.

Incubated within Versant Ventures' Inception Sciences drug discovery operation, Chinook Therapeutics Inc. (Vancouver, B.C.) is developing precision medicines for kidney disorders, and hopes to

Read the full 589 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers